Review World journal of clinical oncology. 2021 Apr 24;12(4):217-237. doi: 10.5306/wjco.v12.i4.217 Q23.22025

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

非小细胞肺癌驱动基因突变的研究：过去、现在和未来 翻译改进

作者单位 +展开

DOI: 10.5306/wjco.v12.i4.217 PMID: 33959476

摘要 Ai翻译

Copyright © World journal of clinical oncology. 中文内容为AI机器翻译，仅供参考！

相关内容

• [Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)]

  中国肺癌基因突变阴性晚期患者免疫治疗专家共识（2022版）

  Society of Cancer Precision Medicine of Chinese Anti-Cancer Association;Lung Cancer Expert Group of Chinese Medical Journal

  Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2022 Oct 23;44(10):1047-1065.

• [Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]

  《中国驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识（2023版）》

  Society of Cancer Precision Medicine of Chinese Anti-Cancer Association;Lung Cancer Expert Group of Chinese Medical Journal

  Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2023 Sep 23;45(9):717-740.

• The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer

  驱动突变对可切除性非小细胞肺癌新辅助免疫治疗效果的影响

  Ziyun Shen et al.

  Cancer immunology, immunotherapy : CII. 2023 Dec;72(12):4235-4247.

• Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients

  中国非小细胞肺癌患者中驱动基因突变的全面调查研究

  Rui Wang et al.

  Oncotarget. 2015 Oct 27;6(33):34300-8.

• Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages

  不同临床分期非小细胞肺癌患者中的致癌驱动基因突变

  J X Zhou et al.

  Annals of oncology : official journal of the European Society for Medical Oncology. 2013 May;24(5):1319-25.

• Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations

  驱动基因阴性的非小细胞肺癌二线治疗的新进展

  Paul C Barnfield

  Drugs. 2016 Sep;76(14):1321-36.

• The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer

  不同驱动基因突变T1期非小细胞肺癌患者淋巴结转移发生率差异分析

  Zhichao Liu et al.

  Lung cancer (Amsterdam, Netherlands). 2019 Aug:134:218-224.

• Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations

  可靶向癌基因驱动突变的非小细胞肺癌的抗PD-1和抗PD-L1免疫治疗

  Edouard Dantoing et al.

  International journal of molecular sciences. 2021 Jun 11;22(12):6288.